Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 2030355.
- Also identified by PMC identifier 1014397.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease.
Medical subject headings
- Antibodies, Monoclonal
- Antigens, Neoplasm
- Iodine Radioisotopes
- Membrane Glycoproteins
- Meningeal Neoplasms
- Meningitis